TITLE

Possible Fracture Risk With Osteoporosis Drugs

PUB. DATE
December 2010
SOURCE
Biomedical Market Newsletter;12/20/2010, p56
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that the Food & Drug Administration (FDA) is warning about a possible risk of a rare type of thigh bone fracture in people who take drugs known as bisphosphonates to treat osteoporosis. FDA saw increasing cases of femoral fracture in patients taking these prescription medications. The agency has informed that a labeling change for bisphosphonate medications is needed so that medication guide will be given to patients when they pick up their prescription.
ACCESSION #
60123819

 

Related Articles

  • FDA: Possible increased risk of thigh bone fracture with bisphosphonates Labeling change adds warning about possible risks of long-term use of osteoporosis drugs.  // Biomedical Market Newsletter;12/20/2010, p52 

    The article reports that the U.S. Food & Drug Administration (FDA) has warned patients and health care providers about the possible risk of atypical thigh bone (femoral) fracture in patients who take bisphosphonates. It is a class of drugs which is used to prevent and treat osteoporosis....

  • FDA Drug Safety Communication: Safety update for osteoporosis drugs, bisphosphonates, and atypical fractures.  // Biomedical Market Newsletter;12/20/2010, p57 

    The article reports that the Food & Drug Administration (FDA) is warning about a possible risk of a rare type of thigh bone fracture in people who take bisphosphonates, a kind of drugs used for treating osteoporosis. FDA saw increasing cases of femoral fracture in patients taking these...

  • Bisphosphonate label should indicate how long to take the drug, say FDA panels.  // Contemporary OB/GYN;Oct2011, Vol. 56 Issue 10, p19 

    The article reports that the FDA panel has stated that the labeling of bisphosphonates for the treatment of osteoporosis should include more specific information as how long women should use the drug.

  • PAIN AMONG USERS OF ANTI-OSTEOPOROSIS DRUG.  // RN;Feb2008, Vol. 71 Issue 2, p26 

    The article reports that severe bone, muscle and joint pain among users of anti-osteoporosis bisphosphonates, alemdrinate sodium (Fosamax) and ibandronate sodium (Boniva) prompted a U.S. Food and Drug Administration (FDA) alert to ensure that doctors warn their patients of this side effect. Pain...

  • FDA advisory panels call for clarification on duration of bisphosphonate use. Foster, Melissa // Endocrine Today;Oct2011, Vol. 9 Issue 10, p1 

    The article reports that the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) has called for clarifications to the duration of use in bisphosphonate drug labeling.

  • New contraindication added to Reclast drug label.  // Reactions Weekly;9/10/2011, Issue 1368, p3 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) on August 30, 2011 to the drug label for Reclast (zoledronic acid), which caution its association with risks of renal failure in patients with a history of, or risk factors for, renal impairment.

  • Medication Safety and Reliability. Labels for TNF-alpha blockers to warn of potential for infection.  // Formulary;Oct2011, Vol. 46 Issue 10, p449 

    The article reports on a safety communication which was released by the U.S. Food & Drug Administration on September 7, 2011. In the communication the agency announced that it is requiring the prescribing information for all tumor necrosis factor-alpha blockers to include a black-boxed warning...

  • FDA advisers uneasy about long-term bisphosphonate use. Traynor, Kate // American Journal of Health-System Pharmacy;11/1/2011, Vol. 68 Issue 21, p2006 

    The article reports that FDA's panel of experts advised against the long-term use of bisphosphonates for osteoporosis, and suggested that biophosphonate therapy be reevaluated on a periodic basis. It mentions the National Osteoporosis Foundation recommendation on biophosphonate use, and includes...

  • Bisphosphonates for Osteoporosis � Where Do We Go from Here? Whitaker, Marcea; Kehoe, Theresa; Benson, George; Guo, Jia // New England Journal of Medicine;5/31/2012, Vol. 366 Issue 22, p2048 

    The article discusses the findings of a review of the efficacy of the long-term biphosphonate in treating osteoporosis. The review, which was conducted by the U.S. Food and Drug Administration (FDA), found that the benefits of long-term biphosphonate in morphometric and clinical or symptomatic...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics